Can Vorinostat treat HPV?

Vorinostat (Vorinostat) is a histone deacetylating agent approved to treat certain types of lymphoma. However, there is no evidence that vorinostat can directly treat human papilloma virus (HPV) infection. Persistent infection with the high-risk human papillomavirus (HPV) can lead to anogenital and head and neck cancers. Human papillomavirus vaccine is effective in preventing new restrictive infections, but is ineffective against existing infections. It is critical to identify effective inhibitors of preneoplastic human papillomavirus infection.

Currently, the main methods for treating HPV infection include surgery, cryotherapy, laser therapy, topical chemicals, and immunotherapy. Histone deacetylases (HDACs) regulate chromatin structure and transcription and are also required for the progression of chromatin replication forks. Vorinostat is a pan HDAC inhibitor that stabilizes host cell tumor suppressors targeted by the human papillomavirus oncoproteins E6 and E7 and eliminates productive infection with high-risk human papillomavirus in human keratinocyte organotypic cultures. In addition, vorinostat selectively induces apoptosis in human papillomavirus-infected cells by reducing DNA repair response and increasing the pro-apoptotic protein Bim. Vorinostat appears to be a promising treatment.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.